Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can AI spot patient decline before It's obvious?

NCT ID NCT05108376

Knowledge-focused Sponsor: Ottawa Hospital Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 08, 2026 · Last updated Sep 09, 2026 · Updated 1 time

Summary

This trial tests whether a machine-learning tool called the Visensia Safety Index can reliably monitor hospitalized patients' vital signs and alert a rapid response team when a patient starts to deteriorate. The study enrolls adults at high risk of decline, such as those recovering from major surgery or with certain cancers. Researchers will check if the system works technically, how doctors and nurses view it, and whether it might help catch problems earlier than standard methods.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Visensia Safety Index (VSI), a machine-learning predictive monitoring system that analyzes continuous vital sign data to detect early patient deterioration
What this could lead to
If successful, this could pave the way for wider use of AI-driven monitoring to catch patient declines earlier, potentially reducing ICU admissions and improving outcomes.
What could go wrong
This is a small feasibility study, not a proof of effectiveness. The system may not integrate smoothly or may produce too many false alarms, and its impact on patient outcomes remains unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

41 people

The number who actually took part.

Started

Sep 2023

Finished

Mar 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Adult patient (greater than or equal to 18 years of age) designated for the most aggressive levels of potential intervention (Category 1 status - Full Care and Category 2 status - Full Care except CPR) who belong to one of the following groups: * Patients who have undergone high risk elective surgery (Whipple procedures, high risk vascular surgery, high risk general surgery, among others) * Malignant haematology or oncology patients at high risk for deterioration * Patients with infection admitted from the Emergency Department (ED) to the ward * Other high-risk patients determined at the discretion of the clinical team Exclusion Criteria: * Patients admitted to a unit with higher level monitoring (Neurological Acute Assessment Unit, Acute Monitoring Area, Trauma Step-Down, Intensive Care Unit) * Patients with Category III (Full Care except Respiratory or Hemodynamic Life Support, or CPR) or IV status (Comfort Care)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Deterioration, clinical are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Clinical Deterioration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Deterioration, clinical

Contacts and locations

Locations

  • The Ottawa Hospital

    Ottawa, Ontario, K1H 8L6, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.